BTIG Research Reaffirms Buy Rating for Alto Neuroscience (NYSE:ANRO)

Alto Neuroscience (NYSE:ANRO)‘s stock had its “buy” rating reiterated by investment analysts at BTIG Research in a note issued to investors on Wednesday, Benzinga reports. They presently have a $37.00 price objective on the stock. BTIG Research‘s target price would suggest a potential upside of 24.63% from the stock’s previous close.

Several other analysts have also weighed in on ANRO. HC Wainwright upped their target price on Alto Neuroscience from $55.00 to $60.00 and gave the company a “buy” rating in a report on Monday, October 19th. Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Zacks Research raised shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Tuesday, October 27th. Finally, Wedbush raised their target price on shares of Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.88.

Alto Neuroscience Price Performance

Shares of ANRO traded up $1.08 on Wednesday, reaching $29.69. The stock had a trading volume of 249,454 shares, compared to its average volume of 429,271. The firm has a market capitalization of $1.16 billion, a PE ratio of -12.29 and a beta of 1.42. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. The firm has a 50-day moving average of $26.71 and a 200 day moving average of $24.43. Alto Neuroscience has a twelve month low of $10.80 and a twelve month high of $37.48.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.13. Sell-side analysts expect that Alto Neuroscience will post -2.69 EPS for the current year.

Insider Transactions at Alto Neuroscience

In other Alto Neuroscience news, CFO Nicholas Smith sold 24,056 shares of the stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $25.82, for a total transaction of $621,125.92. Following the sale, the chief financial officer owned 24,060 shares in the company, valued at approximately $621,229.20. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 11.25% of the company’s stock.

Institutional Trading of Alto Neuroscience

Several institutional investors and hedge funds have recently made changes to their positions in ANRO. Commodore Capital LP increased its position in Alto Neuroscience by 49.4% during the 1st quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock worth $61,217,000 after purchasing an additional 900,000 shares in the last quarter. Perceptive Advisors LLC boosted its stake in shares of Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after purchasing an additional 225,500 shares during the last quarter. Spruce Street Capital LP boosted its stake in shares of Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock worth $29,116,000 after purchasing an additional 1,102,366 shares during the last quarter. Affinity Asset Advisors LLC acquired a new stake in shares of Alto Neuroscience during the 1st quarter worth about $11,240,000. Finally, Jennison Associates LLC purchased a new stake in shares of Alto Neuroscience during the first quarter worth about $8,687,000.

Alto Neuroscience Company Profile

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.